Experience

SPARX THERAPEUTICS

• United States
• Pharmaceutical Manufacturing
• 1 - 100 Employee

• Senior Vice President and Head of Biology

  • Aug 2020 - Present



AIT Bioscience

• United States
• Pharmaceutical Manufacturing
• 1 - 100 Employee

• VP, Biotherapeutics Development, LBA

  • Jul 2020 - Aug 2020



Indiana Biosciences Research Institute

• United States
• Research Services
• 1 - 100 Employee

• Research Fellow

  • Jul 2018 - Jul 2020

  Part of IBRI Pharmaceutical Biotechnology Center. Led a group of scientists in the discovery and engineering of monoclonal antibodies for optimal PK/PD properties. Part of IBRI Pharmaceutical Biotechnology Center. Led a group of scientists in the discovery and engineering of monoclonal antibodies for optimal PK/PD properties.



Eli Lilly and Company

• United States
• Pharmaceutical Manufacturing
• 700 & Above Employee

• Distinuished Fellow (retired)

  • Jun 1998 - May 2018

  Responsibilities of recently held positions at Eli Lilly and Company include the direction of a team of 30 scientists (12 Ph.D. level) charged with supporting the preclinical development of Lilly’s biotechnology portfolio (monoclonal antibodies, multi-functional antibodies, fusion proteins and peptides). The group was built in a multi-disciplinary fashion to include scientists with backgrounds in immunology, analytical chemistry, biochemistry, protein engineering and pharmacokinetics. The team engaged closely with scientists in the protein engineering department to allow early evaluation and optimization of structure-function relationships in the discovery phase. The group integrated with therapeutic area biologists to develop pre-clinical models and biomarkers to support PK/PD modeling and translation of safe and efficacious doses for initial human studies. Other key responsibilities were to develop bio-analytical methods (ELISA, MSD, Mass-spectrometry) to support preclinical animal studies and human clinical studies through registration phase.

• Distinguished Research Fellow (retired)

  • 1998 - 2018